The Impact of Supplemental Antioxidants on Visual Function in Nonadvanced Age-Related Macular Degeneration: A Head-to-Head Randomized Clinical Trial

被引:40
|
作者
Akuffo, Kwadwo Owusu [1 ]
Beatty, Stephen [1 ]
Peto, Tunde [2 ]
Stack, Jim [1 ]
Stringham, Jim [3 ]
Kelly, David [1 ]
Leung, Irene [4 ,5 ]
Corcoran, Laura [1 ]
Nolan, John M. [1 ]
机构
[1] Waterford Inst Technol, Nutr Res Ctr Ireland, Sch Hlth Sci, Macular Pigment Res Grp, Waterford, Ireland
[2] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland
[3] Univ Georgia, Dept Physiol & Pharmacol, Nutr Neurosci Lab, Athens, GA 30602 USA
[4] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[5] UCL Inst Ophthalmol, London, England
基金
欧洲研究理事会;
关键词
randomized clinical trial; lutein; zeaxanthin; meso-zeaxanthin; macular pigment; age-related macular degeneration; visual function; visual acuity; contrast sensitivity; NEI VFQ-25; photostress recovery time; reading performance; glare disability; retinal straylight; BASE-LINE-CHARACTERISTICS; CONTRAST SENSITIVITY; EYE DISEASE; SURGICAL REMOVAL; ZEAXANTHIN; PIGMENT; LUTEIN; CAROTENOIDS; CATARACT; PREVALENCE;
D O I
10.1167/iovs.16-21192
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. The purpose of this study was to evaluate the impact of supplemental macular carotenoids (including versus not including meso-zeaxanthin) in combination with coantioxidants on visual function in patients with nonadvanced age-related macular degeneration. METHODS. In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso-zeaxanthin; n = 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61). Visual function was assessed using best-corrected visual acuity, contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading performance, and the National Eye Institute Visual Function Questionnaire-25. Macular pigment was measured using customized heterochromatic flicker photometry. RESULTS. There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881). Statistically significant improvements in several secondary outcome visual function measures (letter CS at 1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at 1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time; retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05, for all), and were statistically comparable between interventions (P > 0.05, for all). Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05). CONCLUSIONS. Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function.
引用
收藏
页码:5347 / 5360
页数:14
相关论文
共 50 条
  • [41] Impact of Visual Motion Displayed in a Non-Immersive Head-Mounted Device on the Balance of Patients with Age-Related Macular Degeneration
    Chauvire, Caroline
    Cecilia, Coen
    Koustanai, Arnaud
    Le Brun, Johan
    Pineau, Samuel
    Villette, Thierry
    Chaumet-Riffaud, Philippe
    Mohand-Said, Saddek
    Sahel, Jose
    Safran, Avinoam
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [42] Dietary intake of antioxidants and risk of age-related macular degeneration
    van Leeuwen, R
    Boekhoorn, S
    Vingerling, JR
    Witteman, JCM
    Klaver, CCW
    Hofman, A
    de Jong, PTVM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (24): : 3101 - 3107
  • [43] ARE ANTIOXIDANTS OR SUPPLEMENTS PROTECTIVE FOR AGE-RELATED MACULAR DEGENERATION - IN REPLY
    WEST, SK
    BRESSLER, SB
    BRESSLER, NM
    VITALE, S
    ARCHIVES OF OPHTHALMOLOGY, 1994, 112 (06) : 730 - 730
  • [44] AGE-RELATED MACULAR DEGENERATION AND CATARACT - ARE DIETARY ANTIOXIDANTS PROTECTIVE
    GOLDBERG, J
    FLOWERDEW, G
    TSO, MOM
    BRODY, JA
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 128 (04) : 904 - 905
  • [45] Antioxidants and zinc to prevent progression of age-related macular degeneration
    Jampol, LM
    Ferris, FL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (19): : 2466 - 2468
  • [46] Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration
    Schaal, Karen B.
    Rosenfeld, Philip J.
    Gregori, Giovanni
    Yehoshua, Zohar
    Feuer, William J.
    OPHTHALMOLOGY, 2016, 123 (05) : 1060 - 1079
  • [47] How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care
    Davis, Janet
    Olsen, Timothy W.
    Stewart, Michael
    Sternberg, Paul, Jr.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 152 (04) : 509 - 514
  • [48] Improved vision-related function after ranibizumab treatment of Neovascular age-related macular degeneration - Results of a randomized clinical trial
    Chang, Tom S.
    Bressler, Neil M.
    Fine, Jennifer T.
    Dolan, Chantal W.
    Ward, James
    Klesert, Todd R.
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (11) : 1460 - 1469
  • [49] Clinical Classification of Age-related Macular Degeneration
    Ferris, Frederick L., III
    Wilkinson, C. P.
    Bird, Alan
    Chakravarthy, Usha
    Chew, Emily
    Csaky, Karl
    Sadda, SriniVas R.
    OPHTHALMOLOGY, 2013, 120 (04) : 844 - 851
  • [50] A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration
    Gabrielle, Pierre-Henry
    Delyfer, Marie-Noelle
    Glacet-Bernard, Agnes
    Conart, Jean Baptiste
    Uzzan, Joel
    Kodjikian, Laurent
    Arndt, Carl
    Tadayoni, Ramin
    Soudry-Faure, Agnes
    Garcher, Catherine P. Creuzot
    OPHTHALMOLOGY, 2023, 130 (09) : 947 - 957